bioRxivImmunology
Skin inflammation driven by differentiation of quiescent tissue-resident ILCs into a spectrum of pathogenic effectors
P. Bielecki, S. J. Riesenfeld, M. S. Kowalczyk, M. C. Amezcua Vesely, L. Kroehling, P. Yaghoubi, D. Dionne, A. Jarret, H. R. Steach, H. M. McGee, C. B. M. Porter, P. Licona-Limon, W. Bailis, R. Jackson, N. Gagliani, R. M. Locksley, A. Regev, R. A. Flavell
Abstract
Psoriasis pathology is driven by the type 3 cytokines IL-17 and Il-22, but little is understood about the dynamics that initiate alterations in tissue homeostasis. Here, we use mouse models, single-cell RNA-seq (scRNA-seq), computational inference and cell lineage mapping to show that psoriasis induction reconfigures the functionality of skin-resident ILCs to initiate disease. Tissue-resident ILCs amplified an initial IL-23 trigger and were sufficient, without circulatory ILCs, to drive pathology, indicating that ILC tissue remodeling initiates psoriasis. Skin ILCs expressed type 2 cytokines IL-5 and IL-13 in steady state, but were epigenetically poised to become ILC3-like cells. ScRNA-seq profiles of ILCs from psoriatic and naive skin of wild type (WT) and Rag1-/- mice form a dense continuum, consistent with this model of fluid ILC states. We inferred biological \"topics\" underlying these states and their relative importance in each cell with a generative model of latent Dirichlet allocation, showing that ILCs from untreated skin span a spectrum of states, including a naive/quiescent-like state and one expressing the Cd74 and Il13 but little Il5. Upon disease induction, this spectrum shifts, giving rise to a greater proportion of classical Il5- and Il13- expressing \"ILC2s\" and a new, mixed ILC2/ILC3-like subset, expressing Il13, Il17, and Il22. Using these key topics, we related the cells through transitions, revealing a quiescence-ILC2-ILC3s state trajectory. We demonstrated this plasticity in vivo, combining an IL-5 fate mouse with IL-17A and IL-22 reporters, validating the transition of IL-5-producing ILC2s to IL-22- and IL-17A-producing cells during disease initiation. Thus, steady-state skin ILCs are actively repressed and cued for a plastic, type 2 response, which, upon induction, morphs into a type 3 response that drives psoriasis. This suggests a general model where specific immune activities are primed in healthy tissue, dynamically adapt to provocations, and left unchecked, drive pathological remodeling.
- organism: mouse
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: trajectory inference
- research focus: differential expression
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CD200R1 promotes IL-17 production by ILC3s, by enhancing STAT3 activation
H. Linley, A. Ogden, … A. Saunders·bioRxiv·Apr 17, 2022
- CCR7+ Dendritic Cells Define a Type 17 Module in Psoriasis
Yang Sun, Fangzhou Lou, … Honglin Wang·Nature CommunicationsPeer-reviewed·Aug 15, 2025
- Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses
C. M. Failla, L. Capriotti, … S. Madonna·bioRxiv·Sep 12, 2019
- Modeling of the Network Mediated by IL-36 Involved inPsoriasis
Sneha Pandey, Syona Tiwari, … R. Pandey·bioRxiv·Jul 3, 2023
- IL-23 production is regulated via an MSK1/2 - CREB dependent signaling pathway downstream of Toll like receptors.
K. F. Houslay, M. van Gijsel-Bonnello, … J. S. C. Arthur·bioRxiv·Jul 7, 2020
- Disease context dictates the cellular targets of IL-17 in inflammatory skin disease
Kellen J. Cavagnero, Fengwu Li, … Richard L. Gallo·Journal of Investigative DermatologyPeer-reviewed·Jul 1, 2026